• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by VolitionRX Limited

    5/30/25 4:13:34 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $VNRX alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0000093314
    STANDARD CAPITAL CORP
    STANDARD CAPITAL CORPORATION
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    VOLITIONRX LTD
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    VOLITIONRX LTD
    Street Address 1 Street Address 2
    1489 West Warm Springs Road Suite 110
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    Henderson NEVADA 89014 (646) 650-1351

    3. Related Persons

    Last Name First Name Middle Name
    Reynolds Cameron
    Street Address 1 Street Address 2
    1489 West Warm Springs Road Suite 110
    City State/Province/Country ZIP/PostalCode
    Henderson NEVADA 89014
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Hughes Terig
    Street Address 1 Street Address 2
    1489 West Warm Springs Road Suite 110
    City State/Province/Country ZIP/PostalCode
    Henderson NEVADA 89014
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Rootsaert Rodney
    Street Address 1 Street Address 2
    1489 West Warm Springs Road Suite 110
    City State/Province/Country ZIP/PostalCode
    Henderson NEVADA 89014
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Batchelor Louise
    Street Address 1 Street Address 2
    1489 West Warm Springs Road Suite 110
    City State/Province/Country ZIP/PostalCode
    Henderson NEVADA 89014
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Butera Salvatore Thomas
    Street Address 1 Street Address 2
    1489 West Warm Springs Road Suite 110
    City State/Province/Country ZIP/PostalCode
    Henderson NEVADA 89014
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Forterre Gael
    Street Address 1 Street Address 2
    1489 West Warm Springs Road Suite 110
    City State/Province/Country ZIP/PostalCode
    Henderson NEVADA 89014
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Kway Jasmine
    Street Address 1 Street Address 2
    1489 West Warm Springs Road Suite 110
    City State/Province/Country ZIP/PostalCode
    Henderson NEVADA 89014
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Micallef Jacob
    Street Address 1 Street Address 2
    1489 West Warm Springs Road Suite 110
    City State/Province/Country ZIP/PostalCode
    Henderson NEVADA 89014
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Michel Gaetan
    Street Address 1 Street Address 2
    1489 West Warm Springs Road Suite 110
    City State/Province/Country ZIP/PostalCode
    Henderson NEVADA 89014
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Plummer Nicholas
    Street Address 1 Street Address 2
    1489 West Warm Springs Road Suite 110
    City State/Province/Country ZIP/PostalCode
    Henderson NEVADA 89014
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Retter Andrew
    Street Address 1 Street Address 2
    1489 West Warm Springs Road Suite 110
    City State/Province/Country ZIP/PostalCode
    Henderson NEVADA 89014
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Colman Alan
    Street Address 1 Street Address 2
    1489 West Warm Springs Road Suite 110
    City State/Province/Country ZIP/PostalCode
    Henderson NEVADA 89014
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Henshall Mickie
    Street Address 1 Street Address 2
    1489 West Warm Springs Road Suite 110
    City State/Province/Country ZIP/PostalCode
    Henderson NEVADA 89014
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Innes Guy Archibald
    Street Address 1 Street Address 2
    1489 West Warm Springs Road Suite 110
    City State/Province/Country ZIP/PostalCode
    Henderson NEVADA 89014
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Nguyen Kim
    Street Address 1 Street Address 2
    1489 West Warm Springs Road Suite 110
    City State/Province/Country ZIP/PostalCode
    Henderson NEVADA 89014
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Barnes Phillip
    Street Address 1 Street Address 2
    1489 West Warm Springs Road Suite 110
    City State/Province/Country ZIP/PostalCode
    Henderson NEVADA 89014
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Still Timothy I
    Street Address 1 Street Address 2
    1489 West Warm Springs Road Suite 110
    City State/Province/Country ZIP/PostalCode
    Henderson NEVADA 89014
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Rubin Ethel
    Street Address 1 Street Address 2
    1489 West Warm Springs Road Suite 110
    City State/Province/Country ZIP/PostalCode
    Henderson NEVADA 89014
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
    X Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2025-05-20    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

       Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
       Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
    X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security X Other (describe)
    Common Stock issuable upon conversion of Warrant and Senior Secured Convertible Promissory Note

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number X None
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    Street Address 1 Street Address 2
    City State/Province/Country ZIP/Postal Code
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $16,250,000 USD
    or    Indefinite
    Total Amount Sold $16,250,000 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    The Total Offering Amount reflected above assumes exercise in full of the Warrant and Senior Secured Convertible Promissory Note at a future date

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    0
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    1

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $0 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    VOLITIONRX LTD /s/ Cameron Reynolds Cameron Reynolds President and Chief Executive Officer 2025-05-30

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $VNRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VNRX

    DatePrice TargetRatingAnalyst
    4/8/2025$2.50Buy
    H.C. Wainwright
    2/1/2023Buy → Hold
    The Benchmark Company
    2/17/2022$8.00 → $7.00Overweight
    Cantor Fitzgerald
    11/16/2021$10.00 → $9.00Buy
    Aegis Capital
    More analyst ratings

    $VNRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

      Clinical Paper Published in BMC Veterinary Research HENDERSON, Nev., May 19, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces the publication of "Evaluation of plasma nucleosome concentrations and the effect of pre-analytical variables in healthy cats" in BMC Veterinary Research. This is the first study to report the detection of nucleosomes in cats: previously nucleosome levels have been shown to increase in dogs and humans in certain disease states, including cancer. Frederic Wuilque, Vice President, Global Products, said: "This is an essential step in the development of Nu.Q® products for cats, our third species. This

      5/19/25 8:30:00 AM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

      Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., May 15, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the first quarter ended March 31, 2025.  Volition management will host a conference call tomorrow, May 16 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below. Cameron Reynolds, President and Group Chief Executive Officer, said: "2025 is a pivotal year for Volition as we focus on commercializing our ground breaking Nu.Q® platform in the hum

      5/15/25 5:37:00 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update

      Conference call to take place on Friday, May 16 at 8:30 a.m. U.S Eastern Time Henderson, Nev., May 12, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Friday, May 16 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the first quarter of 2025 and to provide a business update. Details of this event can be found below. Event:   VolitionRx Limited First Quarter 2025 Earnings and Business Update Conference CallDate:     Friday, May 16, 2025 Time:    8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (toll fr

      5/12/25 8:30:00 AM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VNRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on VolitionRx with a new price target

      H.C. Wainwright initiated coverage of VolitionRx with a rating of Buy and set a new price target of $2.50

      4/8/25 8:02:28 AM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • VolitionRx downgraded by The Benchmark Company

      The Benchmark Company downgraded VolitionRx from Buy to Hold

      2/1/23 7:40:33 AM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Cantor Fitzgerald resumed coverage on VolitionRx with a new price target

      Cantor Fitzgerald resumed coverage of VolitionRx with a rating of Overweight and set a new price target of $7.00 from $8.00 previously

      2/17/22 9:10:02 AM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VNRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Micallef Jacob Vincent bought $21,500 worth of shares (50,000 units at $0.43), increasing direct ownership by 13% to 426,033 units (SEC Form 4)

      4 - VOLITIONRX LTD (0000093314) (Issuer)

      5/19/25 1:23:05 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • President and CEO Reynolds Cameron John bought $8,730 worth of shares (20,000 units at $0.44), increasing direct ownership by 0.87% to 2,319,222 units (SEC Form 4)

      4 - VOLITIONRX LTD (0000093314) (Issuer)

      5/19/25 12:43:56 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • President and CEO Reynolds Cameron John bought $100,000 worth of shares (181,818 units at $0.55), increasing direct ownership by 9% to 2,299,222 units (SEC Form 4)

      4 - VOLITIONRX LTD (0000093314) (Issuer)

      3/27/25 8:13:46 AM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VNRX
    SEC Filings

    See more
    • SEC Form D filed by VolitionRX Limited

      D - VOLITIONRX LTD (0000093314) (Filer)

      5/30/25 4:13:34 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 10-Q filed by VolitionRX Limited

      10-Q - VOLITIONRX LTD (0000093314) (Filer)

      5/15/25 5:27:40 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • VolitionRX Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - VOLITIONRX LTD (0000093314) (Filer)

      5/15/25 5:26:48 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VNRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Volition Issues Business Review 2024

      HENDERSON, Nev., Jan. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, has issued a Business Review of 2024, outlining its key highlights from the past year. Volition's major achievements in 2024 include: Expanded access to the Nu.Q® Vet Cancer Test – now available for purchase in 20 countries worldwide.Sold over 110,000 Nu.Q® Vet Cancer Tests in the first three quarters 2024.Hosted Satellite Symposium at European Society of Intensive Care Medicine 2024 showcasing Nu.Q® NETs clinical utility in over 3,000 intensive care sepsis patients.Continued to strengthen our strategic patent portfolio.Made significant progress a

      1/8/25 8:30:00 AM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Volition Appoints Timothy I. Still as Chairman

      HENDERSON, Nev., Nov. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed Timothy Still as Chairman of its board of directors, effective November 06, 2024. Mr. Still is currently Chairman and CEO of TSTILL Enterprises LLC, and an Operating Partner with REVIVAL Healthcare. An accomplished executive with a career spanning over 35 years in medical diagnostics, devices and digital health, his background includes extensive experience in designing and implementing highly focused commercial and business development

      11/6/24 4:10:00 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Volition Appoints Dr. Ethel Rubin as an Independent Director

      HENDERSON, Nev., Sept. 30, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr. Ethel Rubin to its board of directors, as an independent director, effective September 30, 2024. Dr. Rubin has also been appointed as a member of the Audit Committee and the Compensation Committee. Dr. Rubin has over 20 years' experience within the life sciences sector, leading healthcare innovation and commercialization strategies for a wide range of organizations – from early-stage operations to large global corporate businesses

      9/30/24 4:10:00 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VNRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by VolitionRX Limited

      SC 13G - VOLITIONRX LTD (0000093314) (Subject)

      11/14/24 4:05:14 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by VolitionRX Limited

      SC 13G - VOLITIONRX LTD (0000093314) (Subject)

      11/14/24 3:40:04 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by VolitionRX Limited (Amendment)

      SC 13G/A - VOLITIONRX LTD (0000093314) (Subject)

      2/14/24 4:05:45 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VNRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $VNRX
    Financials

    Live finance-specific insights

    See more
    • Chief Scientific Officer Micallef Jacob Vincent bought $21,500 worth of shares (50,000 units at $0.43), increasing direct ownership by 13% to 426,033 units (SEC Form 4)

      4 - VOLITIONRX LTD (0000093314) (Issuer)

      5/19/25 1:23:05 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • President and CEO Reynolds Cameron John bought $8,730 worth of shares (20,000 units at $0.44), increasing direct ownership by 0.87% to 2,319,222 units (SEC Form 4)

      4 - VOLITIONRX LTD (0000093314) (Issuer)

      5/19/25 12:43:56 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Operating Officer Michel Gaetan covered exercise/tax liability with 6,844 shares, decreasing direct ownership by 2% to 388,276 units (SEC Form 4)

      4 - VOLITIONRX LTD (0000093314) (Issuer)

      5/5/25 4:06:10 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

      Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., May 15, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the first quarter ended March 31, 2025.  Volition management will host a conference call tomorrow, May 16 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below. Cameron Reynolds, President and Group Chief Executive Officer, said: "2025 is a pivotal year for Volition as we focus on commercializing our ground breaking Nu.Q® platform in the hum

      5/15/25 5:37:00 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update

      Conference call to take place on Friday, May 16 at 8:30 a.m. U.S Eastern Time Henderson, Nev., May 12, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Friday, May 16 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the first quarter of 2025 and to provide a business update. Details of this event can be found below. Event:   VolitionRx Limited First Quarter 2025 Earnings and Business Update Conference CallDate:     Friday, May 16, 2025 Time:    8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (toll fr

      5/12/25 8:30:00 AM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update

      Conference call to take place on Monday, March 31 at 4:30 p.m. U.S Eastern Time HENDERSON, Nev., March 25, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Monday, March 31 at 4.30 p.m. U.S. Eastern Time to discuss its financial and operating results for the fourth quarter and full fiscal year 2024, in addition to providing a business update. Details of this event can be found below. Event: VolitionRx Limited Full Fiscal Year 2024 Earnings and Business Update Conference CallDate: Monday, March 31, 2025Time: 4:30 p.m. U.S. Eastern Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (toll fre

      3/25/25 9:30:00 AM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care